GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) shares crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $21.66 and traded as low as $20.50. GENMAB A/S/S shares last traded at $20.76, with a volume of 1,380,277 shares traded.
GENMAB A/S/S Price Performance
The firm’s 50-day moving average price is $21.57 and its 200-day moving average price is $24.62.
About GENMAB A/S/S
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Further Reading
- Five stocks we like better than GENMAB A/S/S
- What Are Dividend Challengers?
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
- The Role Economic Reports Play in a Successful Investment Strategy
- Power Play: Japan’s Top Auto Stocks Eye Historic Merger
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- S&P 500 Earnings Set to Shine: January’s Critical Market Test
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
